207304-86-7

Basic information

• Product Name: (2S,4S)-1-CBZ-4-aMino Pyrrolidine-2-carboxylic acid Methylester-HCl
• Synonyms: (2S,4S)-1-CBZ-4-aMino Pyrrolidine-2-carboxylic acid Methylester-HCl;Methyl (2S,4S)-1-Cbz-4-aMinopyrrolidine-2-carboxylate hydrochloride
• CAS NO: 207304-86-7
• Molecular Formula: C₁₄H₁₈N₂O₄
• Molecular Weight: 314.76466
• Mol File: 207304-86-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2S,4S)-1-CBZ-4-aMino Pyrrolidine-2-carboxylic acid Methylester-HCl(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4S)-1-CBZ-4-aMino Pyrrolidine-2-carboxylic acid Methylester-HCl(207304-86-7)
• EPA Substance Registry System: (2S,4S)-1-CBZ-4-aMino Pyrrolidine-2-carboxylic acid Methylester-HCl(207304-86-7)

Safety Data

• Hazardous Substances Data: 207304-86-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(2S,4S)-1-CBZ-4-amino Pyrrolidine-2-carboxylic acid methylester-HCl is used as a key intermediate in the synthesis of pharmaceuticals for its ability to protect the amino group during peptide assembly, facilitating the creation of complex peptide structures with desired bioactivity.
Used in Peptide Synthesis:
In the field of peptide chemistry, (2S,4S)-1-CBZ-4-amino Pyrrolidine-2-carboxylic acid methylester-HCl is utilized as a protecting agent for the amino group, enabling selective reactions at the carboxyl group and contributing to the successful synthesis of specific peptide sequences.
Used in Bioactive Compound Production:
(2S,4S)-1-CBZ-4-amino Pyrrolidine-2-carboxylic acid methylester-HCl is employed as a precursor in the production of bioactive compounds, leveraging its optical activity and reactivity to create molecules with potential therapeutic or biological significance.

Upstream product

• 113490-74-7 4(S)-azido-N-<(phenylmethoxy)carbonyl>-(S)-proline methyl ester 
• 64187-48-0 methyl (2S,4R)-1-benzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylate 
• 117811-78-6 methyl (2S,4R)-1-benzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-carboxylate 
• 501-53-1 benzyl chloroformate 
• 51-35-4 4R-4-hydroxyproline 
• 13504-85-3 (2S,4R)-1-(benzyloxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid 
• 1499-56-5 (R)-4-hydroxy-L-proline ethyl ester 

Downstream Products

• 168263-80-7 methyl (2S,4S)-1-benzyloxycarbonyl-4-tert-butoxycarbonylaminopyrrolidine-2-carboxylate 
• 663948-85-4 tert-butyl ((3S,5S)-5-(hydroxymethyl)pyrrolidin-3-yl)carbamate 
• 380648-94-2 benzyl (2S,4S)-4-((tert-butoxycarbonyl)amino)-2-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 380648-96-4 {1-[2-((2S,4S)-4-tert-Butoxycarbonylamino-2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl]-2-oxo-1,2-dihydro-pyrimidin-4-yl}-carbamic acid benzyl ester 
• 380648-97-5 {(2S,4S)-4-t-butoxycarbonylamino-1-[(thymin-1-yl)methylcarbonyl]-pyrrolidin-2-yl}methyl 4-nitrophenyl carbonate 
• 380648-98-6 carbonic acid 1-[(4-benzyloxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-acetyl]-4-tert-butoxycarbonylamino-pyrrolidin-2-ylmethyl ester 4-nitro-phenyl ester 
• 1321614-25-8 methyl (4S)-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}-L-prolinate 
• 1321614-31-6 methyl (4S)-1-[(2S)-3-(acetylsulfanyl)-2-methylpropanoyl]-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}-L-prolinate 
• 1321614-34-9 (4S)-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline 
• 1321614-42-9 methyl N-[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-(4S)-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}-L-prolinate 
• 1321614-45-2 N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-(4S)-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}-L-proline 

Relevant articles and documents

DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE

Provided herein are a dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B. Specifically, provided herein is a compound having Formula (I) or (Ia), or a stereisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.

PROLINE DERIVATIVES FOR USE IN THE TREATMENT OF DIABETES

The present invention provides novel heterocyclic compounds and methods of preparing such compounds. The compounds of the invention are useful for palliative, curative or prophylactic treatment of diseases or conditions of diabetes and/or hypertension. This invention also relates to pharmaceutical compositions containing the compounds of the present invention, and methods for palliative, curative or prophylactic treatment of diseases or conditions of diabetes and/or hypertension. The present invention also provides pharmaceutical compositions consisting of the heterocyclic compounds along with one or more dyslipidemic agents, antiobesity agents, anti-hyperglycemic agents, antihypertensive agents and anti-inflammatory agents.

Discovery and synthesis of HIV integrase inhibitors: Development of potent and orally bioavailable N-methyl pyrimidones

The human immunodeficiency virus type-1 (HIV-1) encodes three enzymes essential for viral replication: a reverse transcriptase, a protease, and an integrase. The latter is responsible for the integration of the viral genome into the human genome and, therefore, represents an attractive target for chemotherapeutic intervention against AIDS. A drug based on this mechanism has not yet been approved. Benzyl-dihydroxypyrimidine-carboxamides were discovered in our laboratories as a novel and metabolically stable class of agents that exhibits potent inhibition of the HIV integrase strand transfer step. Further efforts led to very potent compounds based on the structurally related N-Me pyrimidone scaffold. One of the more interesting compounds in this series is the 2-N-Me-morpholino derivative 27a, which shows a CIC95 of 65 nM in the cell in the presence of serum. The compound has favorable pharmacokinetic properties in three preclinical species and shows no liabilities in several counterscreening assays.

Pyrrolidine carbamate nucleic acids: Synthesis and DNA binding studies

An efficient solid phase synthesis of pyrrolidine carbamate nucleic acids is reported. The protected (2S, 4S)-4-aminopyrrolidine-2-methanol with nucleobases thymine and cytosine attached to the ring nitrogen through an acetyl linker can be activated as ni

Synthesis and evaluation of prolyl carbamate nucleic acids (PrCNA)

Carbamate linked prolyl nucleic acids are obtained in high yield and purity under mild conditions in solution and solid phase. p-Nitrophenylchloroformate is used as the activating reagent for alcohol. Homooligomers of PrCNA do not bind to DNA. The introduction of this modification in PNA sequences destabilizes the triplxes, inspite of enhancement in the base stacking.